First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to EnrollCAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE...
Month: August 2025
Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy
New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathwayWHITE PLAINS, N.Y., Aug. 20,...
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO...
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative...
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Sai Life Sciences secures SBTi validation for near-term climate targets
Sai Life Sciences Sai Life Sciences HYDERABAD, India, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306...
337,000 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at...
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies...
Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution
Louvain-La-Neuve, Belgium, August 20, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and...
Dallas Premier No Surgery Hair Replacement Folicure Hair Helps Men Reclaim Their Confidence in New Guide to Recognizing When Hair Loss Calls for Action
Discover Best Dallas Premier No Surgery Hair Replacement guide to identifying hair loss and exploring tailored hair replacement solutions to...
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic...
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Investment to support NovaBay’s continued public listing and provide funding for a future strategic transactionEMERYVILLE, Calif., Aug. 19, 2025 (GLOBE...
Scientific Industries Reports Financial Results for Second Quarter of Fiscal Year 2025
TORBAL DIVISION SALES UP 11%SECURED $10 MILLION IN STRATEGIC DIVESTURE OF GENIE PRODUCT LINEVIVID AND BIOPROCESSING NEW PRODUCT AI ROADMAP...
Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient...
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic...
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15,...
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd...